[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PA8784701A1 - Proceso y dispersión sólida que contiene revaprazan para la preparación del mismo - Google Patents

Proceso y dispersión sólida que contiene revaprazan para la preparación del mismo

Info

Publication number
PA8784701A1
PA8784701A1 PA20088784701A PA8784701A PA8784701A1 PA 8784701 A1 PA8784701 A1 PA 8784701A1 PA 20088784701 A PA20088784701 A PA 20088784701A PA 8784701 A PA8784701 A PA 8784701A PA 8784701 A1 PA8784701 A1 PA 8784701A1
Authority
PA
Panama
Prior art keywords
preparation
solid dispersion
revapraze
same
dispersion containing
Prior art date
Application number
PA20088784701A
Other languages
English (en)
Inventor
Park Young-Joon
Hyun Chang-Keun
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of PA8784701A1 publication Critical patent/PA8784701A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UNA DISPERSIÓN SÓLIDA EN DONDE LAS PARTÍCULAS DE REVAPRAZAN SON MODIFICADAS EN LA SUPERFICIE CON UN POLÍMERO SOLUBLE EN AGUA, UN SACÁRIDO SOLUBLE EN AGUA, UN SURFACTANTE O UNA MEZCLA DE ESO Y UN PROCESO PARA LA PREPARACIÓN DE LA MISMA.LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE DISPERSIÓN SÓLIDA Y UN PROCESO PARA LA PREPARACIÓN DE LA COMPOSICIÓN FARMACÉUTICA.
PA20088784701A 2006-12-22 2008-06-13 Proceso y dispersión sólida que contiene revaprazan para la preparación del mismo PA8784701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060132722 2006-12-22
KR1020070135270A KR100954828B1 (ko) 2006-12-22 2007-12-21 레바프라잔 함유 고체분산체 및 그의 제조방법

Publications (1)

Publication Number Publication Date
PA8784701A1 true PA8784701A1 (es) 2009-07-23

Family

ID=39562674

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088784701A PA8784701A1 (es) 2006-12-22 2008-06-13 Proceso y dispersión sólida que contiene revaprazan para la preparación del mismo

Country Status (20)

Country Link
US (1) US8663658B2 (es)
EP (1) EP2101737B1 (es)
JP (1) JP5484910B2 (es)
KR (1) KR100954828B1 (es)
CN (1) CN101600419B (es)
AR (1) AR067084A1 (es)
AU (1) AU2007339080B2 (es)
BR (1) BRPI0720472A2 (es)
CA (1) CA2673536A1 (es)
ES (1) ES2496166T3 (es)
HK (1) HK1138517A1 (es)
MX (1) MX2009006105A (es)
MY (1) MY146557A (es)
PA (1) PA8784701A1 (es)
PE (1) PE20090424A1 (es)
RU (1) RU2461382C2 (es)
SA (1) SA08290368B1 (es)
TW (1) TW200927124A (es)
WO (1) WO2008078922A1 (es)
ZA (1) ZA200905094B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007339080B2 (en) 2006-12-22 2012-09-27 Yuhan Corporation Revaprazan-containing solid dispersion and process for the preparation thereof
CN101874775B (zh) * 2010-05-31 2013-03-13 沈阳药科大学 盐酸瑞伐拉赞纳米混悬剂及其制备方法
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
KR101739815B1 (ko) * 2010-12-01 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물
KR101730865B1 (ko) 2011-02-11 2017-04-27 주식회사유한양행 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
KR101739818B1 (ko) * 2011-05-20 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물
KR101739820B1 (ko) * 2012-03-28 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
WO2015175505A1 (en) * 2014-05-15 2015-11-19 Lundbeck Llc Tetrabenazine modified release formulation
WO2015193309A1 (en) * 2014-06-18 2015-12-23 F. Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
CN104825410A (zh) * 2015-05-04 2015-08-12 海南海力制药有限公司 一种盐酸瑞伐拉赞片及其制备方法
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN105288636B (zh) * 2015-12-11 2019-05-07 北京科莱博医药开发有限责任公司 增溶体系、固体分散体及药物制剂
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions
CN105687150B (zh) * 2016-03-15 2019-12-10 常州市第四制药厂有限公司 一种盐酸瑞伐拉赞组合物及制备方法
CN106361721A (zh) * 2016-08-31 2017-02-01 佛山市弘泰药物研发有限公司 一种盐酸瑞伐拉赞胶囊及其制备方法
PT110585B (pt) * 2018-02-22 2021-04-22 Hovione Farmaciencia Sa Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização
US20220023216A1 (en) 2019-06-26 2022-01-27 Ricoh Company, Ltd. Instantly soluble particle and method for producing the same
WO2020261619A1 (ja) 2019-06-26 2020-12-30 株式会社リコー 医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255125A (ja) 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
ES2201112T3 (es) * 1994-08-13 2004-03-16 Yuhan Corporation Nuevos derivados de pirimidina y procedimientos para su preparacion.
KR0157075B1 (ko) * 1994-08-13 1998-11-16 김태훈 신규의 피리미딘 유도체 및 그의 제조방법
WO1996041628A1 (fr) * 1995-06-12 1996-12-27 Ono Pharmaceutical Co., Ltd. Granules contenant du pranlukast, procede de production des granules et procede de reduction de la cohesion du pranlukast
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
IT1294760B1 (it) 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
DK1227797T3 (da) * 1999-11-12 2005-05-30 Abbott Lab Farmaceutiske faststofdispersionsformuleringer
EP1239831B1 (en) * 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
AU7105501A (en) * 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
ATE243028T1 (de) * 2001-07-11 2003-07-15 Applied Pharma Res Fettlösliche substanzen enthaltende granulate und verfahren zu ihrer herstellung
PL371319A1 (en) * 2002-01-11 2005-06-13 Takeda Pharmaceutical Company Limited Coumarin derivatives, process for their production and use thereof
MXPA05006802A (es) * 2002-12-19 2005-09-08 Pharmacia Corp Formulacion no higroscopica que comprende un farmaco higroscopico.
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
KR101118930B1 (ko) * 2003-11-14 2012-03-14 아지노모토 가부시키가이샤 페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제
CA2582767C (en) 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
AU2007339080B2 (en) 2006-12-22 2012-09-27 Yuhan Corporation Revaprazan-containing solid dispersion and process for the preparation thereof

Also Published As

Publication number Publication date
SA08290368B1 (ar) 2011-10-08
EP2101737A1 (en) 2009-09-23
MY146557A (en) 2012-08-30
TW200927124A (en) 2009-07-01
MX2009006105A (es) 2009-06-18
EP2101737B1 (en) 2014-06-18
US20100041688A1 (en) 2010-02-18
CA2673536A1 (en) 2008-07-03
AU2007339080B2 (en) 2012-09-27
CN101600419A (zh) 2009-12-09
PE20090424A1 (es) 2009-05-15
ZA200905094B (en) 2010-09-29
KR20080059083A (ko) 2008-06-26
KR100954828B1 (ko) 2010-04-27
JP5484910B2 (ja) 2014-05-07
AR067084A1 (es) 2009-09-30
JP2010513474A (ja) 2010-04-30
RU2009128206A (ru) 2011-01-27
AU2007339080A1 (en) 2008-07-03
RU2461382C2 (ru) 2012-09-20
EP2101737A4 (en) 2013-05-01
WO2008078922A1 (en) 2008-07-03
HK1138517A1 (en) 2010-08-27
CN101600419B (zh) 2012-05-09
ES2496166T3 (es) 2014-09-18
BRPI0720472A2 (pt) 2014-01-14
US8663658B2 (en) 2014-03-04

Similar Documents

Publication Publication Date Title
PA8784701A1 (es) Proceso y dispersión sólida que contiene revaprazan para la preparación del mismo
AR081272A1 (es) Procedimiento hims modificado
MX2018006031A (es) Fibra sintetica que contiene aerogel y material de polimero, y metodos de fabricacion y articulos que comprenden los mismos.
MX2010012074A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida.
BR112018067962A2 (pt) artigos absorventes
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
MX2017004581A (es) Estructuras fibrosas perforadas y metodos para fabricarlas.
CL2008001753A1 (es) Proceso para preparar biomasa solida para procesamiento de una mezcla acuosa que comprende triturar la biomasa, agregar un agente de dispersion y contactarla con un catalizador.
WO2006127768A3 (en) Microscale micropatterned engineered in vitor tissue
WO2007136552A3 (en) Compatibilized polymer processing additives
CA3010667A1 (en) Use of 4-bora-3a,4a-diaza-s-indacenes for security purposes
BR112014016705A2 (pt) método de caracterização de materiais encrespados
PH12015501127A1 (en) Abrasive coatings for peroxide-coantaining compositions
CL2016002065A1 (es) Proceso para la preparacion de un producto de relleno mineral.
CL2016002095A1 (es) Proceso para la preparación de un producto rellenador mineral
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
CA124321S (en) Mixer for viscous materials
CO6630089A2 (es) Composicion de encapsulamiento de liberacion rapida
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
GT200600106A (es) Agentes endoparasiticidas
PH12015501013A1 (en) Bar soap composition and method of manufacture
CL2007003857A1 (es) Metodo para eliminar arsenico que comprende lixiviar el material que lo contiene con agente que contiene compuesto de tierras raras, obtener solucion arsenicada y solidos libres de as, contactar solucion con agente precipitante, obtener solucion libre de as y precipitante arsenicado y separar precipitante de solucion; y aparato.
IN2014DN10307A (es)
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
BR112017014083A2 (pt) artigos abrasivos e métodos para formar os mesmos